E-ISSN: 2147-2688
Are Uric Acid Level and Uric Acid/Creatinine Ratio Reliable Biomarkers for Idiopathic Parkinson’s Disease Severity?
PDF
Cite
Share
Request
Original Article
VOLUME: 58 ISSUE: 4
P: 315-319
September 2020

Are Uric Acid Level and Uric Acid/Creatinine Ratio Reliable Biomarkers for Idiopathic Parkinson’s Disease Severity?

Med Bull Haseki 2020;58(4):315-319
DOI: 10.4274/haseki.galenos.2020.5903
Vasfiye Burcu Albay
Mesude Tütüncü
1. Prof. Dr. Mazhar Osman Bakırköy Ruh Sağlığı ve Sinir Hastalıkları Hastanesi, Nöroloji Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 16.01.2020
Accepted Date: 08.04.2020
Publish Date: 10.09.2020
PDF
Cite
Share
Request

ABSTRACT

Conclusion:

Despite corrected age and L-Dopa dose, UA and UCR did not differ between the stages. UA and UCR used as biomarkers of disease severity may not always yield accurate results.

Results:

There were 39 ES, 33 MS, 28 AS patients. The mean UA level was 4.9±1.26 in ES, 5.02±1.22 in MS and 5.1±1.64 in AS (p=0.85). The mean UCR was 5.91±1.78 in ES, 6.03±1.66 in MS and 5.72±1.73 in AS (p=0.79). When corrected age was 67.42, there was no difference in UA (p=0.93), creatinine (p=0.92) and UCR (p=0.91). When corrected L-Dopa dose was 561.18, there was no difference in UA (p=0.99), creatinine (p=0.51) and UCR (p=0.21). When age and L-Dopa were corrected, there was no difference in UA (p=0.96), creatinine (p=0.82) and UCR (p=0.21).

Methods:

Patients were grouped as early stage (ES) (Hoehn-Yahr (HY); 1-2), middle stage (MS) (HY; 2.5-3) and advanced stage (AS) (HY; 4-5). UA levels and UCR were compared between the groups. After age and L-dopa dose were corrected, differences between the groups were recalculated.

Aim:

It has been proposed that elevated levels of uric acid (UA) has a protective effect against the development of Idiopathic Parkinson’s Disease (IPD), however, since IPD has been found to be more common in gout patients, their relationship became controversial. Our aim was to investigate the relationship of UA level and UA-to-creatinine ratio (UCR) with IPD stages and their effects on disease severity.

References

1
Gürbüz M, Akdağ G, Arıcı-Düz O, Özer F, Çokar Ö, Hanoğlu L. Parkinson Hastalığında Apatinin Motor ve Non-motor Bulgularla İlişkisi. Med Bull Haseki 2019;57:129-34.
2
Özkan S. Parkinson Hastalığının Etiyolojisi. Turkiye Klinikleri J Neurol-Special Topics 2008;1:6-14.
3
Fang P, Li X, Luo JJ, Wang H, Yang XF. A Double-edged Sword: Uric Acid and Neurological Disorders. Brain Disord Ther 2013;2:109.
4
Heo SH, Lee SH. High levels of serum Uric acid are associated with silent brain infarction. J Neurol Sci 2010;297:6-10.
5
Pakpoor J, Seminog OO, Ramagopalan SV, Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson’s disease, motor neuron disease: record-linkage studies. BMC Neurol 2015;15:16.
6
Zhang F, Zhang Q, Ke Y, et al. Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep 2018;8:1100.
7
Erdal A, Genç F. Parkinson Hastalığında Ürik Asit Seviyesinin Cinsiyet Ve Hastalık şiddeti ile İlişkisi. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 2018;5:1-3.
8
Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat Disord 2013;19:1027-32.
9
Zhong LL, Song YQ, Tian XY, Can H, Ju KJ. Level of uric acid and uric acid/creatinine ratios in correlation with stage of Parkinson disease. Medicine (Baltimore) 2018;97:e10967.
10
Akbayır E, Şen M, Ay U, Şenyer S, Tüzün E, Küçükali Cİ. Parkinson Hastalığının Etyopatogenezi. Deneysel Tıp Dergisi 2017;7:1-23.
11
Tasdemir E. Parkinson Hastalığında Nöroinflamasyonun Rolü. Med J SDU 2019:26:348-52.
12
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
13
Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002;22:1402-8.
14
Becker BF, Kastenbauer S, Ködel U, Kiel D, Pfister HW. Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system. Nucleosides Nucleotides Nucleic Acids 2004;23:1201-4.
15
Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010;19:1331-6.
16
Kim TH, Lee JH. Serum uric acid and nigral iron deposition in Parkinson’s disease: a pilot study. PLoS One 2014;9:e112512.
17
Lee JE, Song SK, Sohn YH, et al. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011;26:1533-6.
18
Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson’s disease. PLoS One 2012;7:e37331.
19
Chen X, Burdett TC, Desjardins CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300-5.
20
Sampat R, Young S, Rosen A, et al. Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (Vienna) 2016;123:365-70.
21
Gao X, O’Reilly ÉJ, Schwarzschild MA, Ascheriot A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurol 2016;86:520-6.
22
Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2019;34:1464-70.
23
Singh JA, Cleveland JD. Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data. BMC Neurol 2019;19:4.
24
Mehrpour M, Khuzan M, Najimi N, Motamed MR, Fereshtehnejad SM. Serum uric acid level in acute stroke patients. Med J Islam Repub Iran 2012;26:66-72.